Analysts Set Alector, Inc. (NASDAQ:ALEC) Target Price at $3.75

Shares of Alector, Inc. (NASDAQ:ALEC) have been assigned an average rating of “Hold” from the seven brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $3.75.

ALEC has been the subject of a number of recent analyst reports. HC Wainwright lowered their price target on shares of Alector from $35.00 to $7.00 and set a “buy” rating for the company in a report on Friday, November 29th. BTIG Research lowered their price target on shares of Alector from $16.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Stifel Nicolaus lowered shares of Alector from a “buy” rating to a “hold” rating and set a $4.00 price objective for the company. in a report on Monday, December 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Alector in a report on Tuesday, November 26th. Finally, Morgan Stanley lowered shares of Alector from an “equal weight” rating to an “underweight” rating and decreased their price objective for the stock from $10.00 to $3.00 in a report on Tuesday, November 26th.

Insider Buying and Selling

In related news, CEO Arnon Rosenthal sold 52,172 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $2.52, for a total value of $131,473.44. Following the completion of the transaction, the chief executive officer now directly owns 2,507,074 shares in the company, valued at $6,317,826.48. This trade represents a 2.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Marc Grasso sold 16,489 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $2.52, for a total transaction of $41,552.28. Following the completion of the transaction, the chief financial officer now owns 330,651 shares of the company’s stock, valued at approximately $833,240.52. The trade was a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 95,161 shares of company stock worth $239,806 in the last three months. 9.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ALEC. Tower Research Capital LLC TRC increased its stake in shares of Alector by 71.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company’s stock worth $28,000 after acquiring an additional 6,096 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in Alector during the 3rd quarter valued at about $29,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Alector during the 3rd quarter valued at about $40,000. Apollon Wealth Management LLC purchased a new stake in Alector during the 4th quarter valued at about $47,000. Finally, Vontobel Holding Ltd. grew its position in Alector by 127.3% during the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock valued at $47,000 after purchasing an additional 14,000 shares during the last quarter. 85.83% of the stock is currently owned by institutional investors.

Alector Stock Up 1.8 %

NASDAQ:ALEC opened at $1.70 on Friday. The company has a fifty day moving average of $1.82 and a 200 day moving average of $3.74. Alector has a 52 week low of $1.55 and a 52 week high of $7.58. The firm has a market capitalization of $166.48 million, a P/E ratio of -1.00 and a beta of 0.61.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.